SCHEMBL10244110

SCHEMBL10244110

COC(=O)NCCNC(C)c1cc(OC)c(O)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
PKM P14618 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
MEN1 O00255 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
DNM1 Q05193 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244323 0.85 SLC22A3 (0.51) GAALMNASLC22A3CYP3A4
SCHEMBL10243841 0.84 ADRB2 (0.39) KMT2AALDH1A1LMNACA12CA1
SCHEMBL10244285 0.78 ESR1 (0.42) PKMALDH1A1LMNACA12CA1
SCHEMBL10243848 0.76 OPRK1 (0.44) KMT2AKDM4EGAALMNA
SCHEMBL10243804 0.76 OPRK1 (0.44) KMT2AKDM4EGAALMNA
SCHEMBL10244507 0.76 MAPT (0.41) KMT2AKDM4EALDH1A1LMNAMEN1
SCHEMBL10244611 0.75 HPGD (0.49) LMNACA1CA2POLB
SCHEMBL10243687 0.75 CASR (0.56) KMT2AMEN1POLBCYP3A4CYP2D6
SCHEMBL10243926 0.74 PKM (0.46) PKMALDH1A1LMNACYP2D6CYP2C9
SCHEMBL10244522 0.72 RRM1 (0.42) ALDH1A1LMNASLC22A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KMT2A 939/4885PKM 4614/4885KDM4E 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.